Background Therapy level of resistance remains 1 of the main problems

Background Therapy level of resistance remains 1 of the main problems to improve the treatment of sufferers with pancreatic tumor. Bottom line a SP was identified by us in individual PDAC and uncovered a chemoresistant and CSC-associated phenotype. This SP might represent a new therapeutic target in pancreatic cancer. Trial enrollment Clinicaltrials.gov “type”:”clinical-trial”,”attrs”:”text”:”NCT00936104″,”term_id”:”NCT00936104″NCT00936104 in these… Continue reading Background Therapy level of resistance remains 1 of the main problems

O157 and six additional serogroups of Shiga toxin-producing (STEC) (O26 O45

O157 and six additional serogroups of Shiga toxin-producing (STEC) (O26 O45 O103 O111 O121 and O145) account for the majority of STEC infections in the United States. 20 deaths in the United States (40). More than one-third of the total illnesses and all of the deaths are A-769662 caused by O157:H7 the most common and… Continue reading O157 and six additional serogroups of Shiga toxin-producing (STEC) (O26 O45